Roche (SWX: ROP; OTCMKTS: RHHBY) today reported its financial results for the first nine months of 2026. Group sales reached CHF 46.493 billion (~USD 56.3 billion), a 6% increase at constant exchange rates (CER), with third‑quarter sales of CHF 16.13 billion (~USD 19.5 billion), up 7% at CER. The Pharmaceuticals Division served as the main growth driver (+7% at CER), Ocrevus remained the top product contributor (CHF 5.317 billion, +7%), and the company confirmed its full‑year guidance.
Financial Results Snapshot – 9M & Q3 2026
| Item | Result | Growth (CER) |
|---|---|---|
| Group Sales (9M) | CHF 46.493 billion (~USD 56.3 billion) | +6% |
| Group Sales (Q3) | CHF 16.13 billion (~USD 19.5 billion) | +7% |
| Pharmaceuticals Division (9M) | CHF 36.212 billion (~USD 43.9 billion) | +7% |
| Diagnostics Division (9M) | CHF 10.281 billion (~USD 12.5 billion) | +4% |
| Full‑Year Guidance | Confirmed | – |
Pharmaceuticals Division – Geographic Performance
- United States: Contributed more than half of pharma revenues at CHF 18.712 billion (+5%) – the division’s largest market by far.
- Japan: The fastest‑growing major region, with sales up 25%.
- International Markets: Up 10%, adding breadth to the growth profile.
- Europe: Up 2%, a steadier contribution to divisional expansion.
Diagnostics Division – Segment Performance
- Overall: Sales of CHF 10.281 billion (~USD 12.5 billion), up 4% at CER, keeping overall growth positive.
- Pathology Lab: The division’s top engine, up 10%.
- Core Lab: Up 5%.
- Asia‑Pacific: Declined 4%, pressured by healthcare pricing reforms in China – a regional headwind that did not derail divisional growth.
Product Performance – Top Contributors & Growth Drivers
| Product | Indication | 9M Sales / Growth |
|---|---|---|
| Ocrevus | Multiple sclerosis | CHF 5.317 billion (~USD 6.4 billion), +7% – top contributor |
| Hemlibra | Hemophilia | CHF 3.750 billion, +12% – #2 |
| Vabysmo | Eye disease | CHF 3.196 billion, +10% – #3 |
| Columvi | Blood cancer (bispecific antibody) | +67% – fastest‑growing |
| Polivy | Blood cancer | +24% |
| Xolair | Allergic/immunologic conditions | +20% |
| Phesgo | Breast cancer | +18% |
- Growth Engine: Together, the top five growth drivers generated CHF 16.8 billion in sales (+12% at CER).
- Patent Cliff Offset: This momentum effectively offset declines from older products such as Perjeta and Kadcyla driven by patent expirations – evidence of a successful lifecycle transition.
R&D Pipeline & Strategic Milestones
- Late‑Stage Momentum: CEO Thomas Schinecker noted that five potential new medicines entered late‑stage development this year, keeping Roche on track for its target of launching up to 20 new medicines by 2030.
- Fenebrutinib (oral BTK inhibitor, multiple sclerosis): Granted US FDA Priority Review.
- Giredestrant (breast cancer): US approval expected within the year.
- Elecsys pTau217 blood test: Received FDA approval for Alzheimer’s disease, advancing blood‑based diagnostics.
- Enicepetide (dual GLP‑1/GIP receptor agonist): Phase II data showed 15.5% weight loss at 48 weeks without reaching a plateau, signaling Roche’s accelerated entry into the obesity and metabolic disease space.
- US Investment: Progress continues on the USD 50 billion investment plan in US manufacturing and R&D, including a newly announced USD 750 million expansion of the Hillsboro, Oregon injectable manufacturing facility.
Market Impact & Outlook
- Confirmed Guidance: Roche reaffirmed its outlook of mid‑single‑digit CER sales growth for the Group and high‑single‑digit Core EPS growth for the full year.
- Portfolio Transition Working: New growth drivers (Ocrevus, Hemlibra, Vabysmo, Columvi, Polivy) are more than compensating for the Perjeta/Kadcyla patent cliff – a critical test of Roche’s lifecycle strategy.
- Obesity Optionality: The enicepetide Phase II readout positions Roche competitively in the high‑value GLP‑1/GIP metabolic market, one of the largest commercial opportunities in pharma.
- Diagnostics Resilience: Despite China pricing reform pressure in Asia‑Pacific, the division held positive 4% growth, led by Pathology Lab and Core Lab.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Roche’s full‑year 2026 guidance, pipeline milestones including fenebrutinib, giredestrant, and enicepetide, planned product launches by 2030, and US manufacturing investments. Actual results may differ materially due to risks including regulatory decisions, clinical trial outcomes, pricing and reimbursement pressures, foreign‑exchange movements, patent expirations, and competitive dynamics.-Fineline Info & Tech
